2020 Volume 70 Issue 3 Pages 175-185
Twenty years ago, the prognosis of multiple myeloma has been extremely poor, and myeloma was known as incurable disease. However, the treatment performance of myeloma improved by the development of novel agents, including immunomodulatory drugs such as thalidomide, proteasome inhibitor such as bortezomib, and anti-myeloma monoclonal antibody such as daratumumab, and the plateau of survival curve was obtained now. In addition to the improvement of treatment, the new inspection methods of minimal residual disease were developed, and the accuracy of determination of treatment efficacy improved. According to these advances, we now came to be able to make precise therapeutic strategy. Hereafter, the strong immune-therapy including the CAR-T may be introduced in clinical practice, it’s no exaggeration to say that I can expect the cure of myeloma.
